Guiding Principles in Biotech Valuation
The framework institutional investors and major pharmaceutical companies use to assess biotech assets — and what it means for your next raise, deal, or negotiation.
83% of large pharmaceutical companies use Risk-Adjusted Net Present Value (rNPV) as their primary valuation tool. If you're a biotech founder or executive heading into a capital raise, licensing deal, or acquisition process — this is the methodology on the other side of the table.
This report breaks down exactly how it works.
Fill in the form to instantly download the Guiding Principles in Biotech Valuation guide.
What’s Inside the Guide
-
How rNPV differs from standard DCF — and why it matters for early-stage assets
-
Step-by-step breakdown of net cash flow modelling for therapeutic candidates
-
How risk weightings are applied at each development stage (preclinical through regulatory approval)
-
How discount rates are constructed for biotech and drug development companies
-
How market comparables are used as a secondary cross-check — and where they fall short
-
The valuation process used by institutional buyers and major pharma in real transactions
Based on primary academic literature, AusBiotech's Gold Standard framework, and transaction data from 314 global deals.
This report is provided for informational purposes. For a valuation specific to your asset or business, contact Sherwood Australia for a confidential, obligation-free conversation.
Why Sherwood Australia?
✓ AFSL Licence No. 563351 — Sherwood Australia is licensed to provide equity valuations
✓ 250+ valuations delivered across biotech, medtech, AI, and deep tech
✓ Used by founders, investors, and boards across Australia and internationally
Need a Valuation?
We provide fast, professional valuation reports tailored to your needs and sector. Whether you're raising capital, entering a transaction, or simply want clarity on your company’s worth—talk to Sherwood.
Contact Anthony Vago today at anthony@sherwoodaustralia.com.au or +61 406 155 571 for a confidential discussion.
A Proud Member of Sherwood Global Partners
As part of Sherwood Global Partners, we tap into a powerful international network of corporate finance experts, strategic partners, and investors — bringing global opportunity to every transaction.